Determination
of
Statement of Principles
concerning
MESANGIAL
IGA GLOMERULONEPHRITIS
Veterans’ Entitlements Act 1986
1. This
Statement of Principles is determined by the Repatriation Medical Authority
under subsection 196B(2) of the Veterans’ Entitlements Act 1986
(the Act).
Kind of injury, disease or
death
2. (a) This Statement of Principles is about mesangial
IgA glomerulonephritis and death from mesangial IgA glomerulonephritis.
(b)
For the purposes of this Statement
of Principles, “mesangial IgA glomerulonephritis” means a
disease of the kidneys characterised by a predominance of immunohistologically
proven IgA deposits in the renal mesangium and recurring and intermittent
episodes of haematuria or proteinuria. This definition includes primary
mesangial IgA glomerulonephritis and secondary mesangial IgA
glomerulonephritis.
Basis for determining the
factors
3. The Repatriation Medical Authority is of the view that there
is sound medical-scientific evidence that indicates that mesangial IgA glomerulonephritis
and death from mesangial IgA glomerulonephritis can be related to
relevant service rendered by veterans, members of Peacekeeping Forces, or
members of the Forces.
Factors that must be
related to service
4. Subject to clause 6, at least one of the factors set out in
clause 5 must be related to any relevant service rendered by the person.
Factors
5. The factors that must as a minimum exist before it can be said
that a reasonable hypothesis has been raised connecting mesangial IgA
glomerulonephritis or death from
mesangial IgA glomerulonephritis with the circumstances of a person’s
relevant service are:
(a)
for secondary mesangial IgA
glomerulonephritis only, suffering from cirrhosis of the liver at the time of
the clinical onset of mesangial IgA glomerulonephritis; or
(b)
for secondary mesangial IgA
glomerulonephritis only, suffering from Schonlein-Henoch purpura at the time of
the clinical onset of mesangial IgA glomerulonephritis; or
(c)
for primary mesangial IgA
glomerulonephritis only, inhaling or having dermal exposure to:
(i)
oxygenated organic solvents,
(ii)
aliphatic hydrocarbon solvents, or
(iii)
aromatic hydrocarbon solvents,
for an average of at least two hours per week over a
period of at least twelve months before the clinical onset of mesangial IgA
glomerulonephritis; or
(d)
for primary mesangial IgA
glomerulonephritis only, inhaling or having dermal exposure to:
(i)
oxygenated organic solvents,
(ii)
aliphatic hydrocarbon solvents, or
(iii)
aromatic hydrocarbon solvents,
for an average of at least two hours per week over a
period of at least twelve months before the clinical worsening of mesangial IgA
glomerulonephritis; or
(e)
inability to obtain appropriate
clinical management for mesangial IgA glomerulonephritis.
Factors that apply only
to material contribution or aggravation
6. Paragraphs 5(d) to 5(e) apply only to material
contribution to, or aggravation of mesangial IgA glomerulonephritis where the
person’s mesangial IgA glomerulonephritis was suffered or contracted before or
during (but not arising out of) the person’s relevant service; paragraph
8(1)(e), 9(1)(e), 70(5)(d) or 70(5A)(d) of the Act refers.
Inclusion of Statements
of Principles
7. In this Statement of Principles if a relevant
factor applies and that factor includes an injury or disease in respect of
which there is a Statement of Principles then the factors in that last
mentioned Statement of Principles apply in accordance with the terms of that
Statement of Principles.
Other definitions
8. For the purposes of this Statement of Principles:
“cirrhosis of the liver” means a pathologically defined entity involving
irreversible chronic injury of the hepatic parenchyma and includes extensive
fibrosis in association with regenerative nodules;
“death from mesangial IgA glomerulonephritis” in relation to a person includes death from a
terminal event or condition that was contributed to by the person’s mesangial
IgA glomerulonephritis;
“ICD-10-AM code” means a number assigned to a particular kind of injury or disease in
The International Statistical Classification of Diseases and Related Health
Problems, 10th revision, Australian Modification (ICD-10-AM), Second Edition,
effective date of 1 July 2000, copyrighted by the National Centre for
Classification in Health, Sydney, NSW, and having ISBN 1 86487 271 3;
“primary mesangial IgA glomerulonephritis” means predominant IgA mesangial deposits in the
absence of clinical or laboratory evidence of any other associated systemic
disease, and is also known as Berger's disease or idiopathic IgA nephropathy;
“relevant
service” means:
(a) operational
service; or
(b) peacekeeping service; or
(c) hazardous service;
“Schonlein-Henoch purpura” means a systemic vasculitis affecting small calibre
vessels, causing a characteristic clinical syndrome of vascular purpura in the
lower limbs, abdominal pain, joint pain and nephritis;
“secondary mesangial IgA glomerulonephritis” means predominant IgA mesangial deposits in the
presence of clinical or laboratory evidence of any other associated systemic
disease;
“terminal event” means the proximate or ultimate cause of death and
includes:
(a) pneumonia;
(b) respiratory failure;
(c) cardiac arrest;
(d) circulatory failure; or
(e) cessation of brain function.
Notes to Statement of Principles concerning mesangial IgA
glomerulonephritis (Instrument No. 63 of 2001)
The Statement of Principles concerning mesangial IgA
glomerulonephritis (Instrument No. 63 of 2001) in force under section 196B(2)
of the Veterans’ Entitlements Act 1986, as shown in this compilation is
amended as indicated in the Tables below.
Table
of Instruments
|
Title
|
Date of notification
in Gazette or FRLI registration
|
Date of
commencement
|
Application, saving or
transitional provisions
|
|
Statement
of Principles concerning mesangial IgA glomerulonephritis (Instrument No. 63
of 2001)
|
22 August 2001
(see Gazette 2001, No. GN33)
|
22 August 2001
|
|
|
Amendment
of Statement of Principles concerning mesangial IgA glomerulonephritis
(Instrument No. 75 of 2002)
|
27 November 2002
(see Gazette 2002, No. GN47)
|
27 November 2002
|
|
Table of Amendments
|
ad. = added or inserted am. = amended
rep. = repealed rs. = repealed and substituted
|
|
Provision affected
|
How affected
|
|
Paragraph 5(c).....................
|
rs. Instrument No.75 of 2002
|
|
Paragraph 5(d).....................
|
rs. Instrument No.75 of 2002
|
|
Paragraph 8 – ‘organic solvents’............................
|
rep. Instrument No.75 of 2002
|